Auto Injection Technologies v. Novo Nordisk: Voluntary Dismissal in Drug Delivery Patent Case

Case Overview

The Parties

The Patents at Issue

This case involved two U.S. patents covering innovations in medicament injection device mechanisms:

• • US9387294B2 (Application No. US13/498620): Covers innovations in medicament injection device mechanisms
• • US10201662B2 (Application No. US14/782667): Addresses additional design and functional elements of auto-injection platforms

Both patents address technology at the intersection of mechanical engineering and pharmaceutical delivery — a high-value area given the explosive commercial growth of GLP-1-based injectable therapies.

The Accused Products

The complaint targeted medicament injection devices — a product category encompassing auto-injectors, pre-filled pens, and related drug delivery hardware central to Novo Nordisk’s commercial operations. No specific product lines were enumerated in the public record reviewed here.

Legal Representation

Plaintiff’s Counsel: Peter Lambrianakos and Vincent J. Rubino III of Fabricant LLP (New York), a firm known for high-volume patent assertion litigation across multiple technology sectors.

Defendant’s Counsel: Deron R. Dacus of The Dacus Firm PC, a well-regarded East Texas IP litigation boutique with deep experience before Judge Gilstrap.

Litigation Timeline & Procedural History

Auto Injection Technologies filed suit on April 9, 2025, selecting the Eastern District of Texas — historically the nation’s most plaintiff-friendly patent venue and home to Chief Judge Rodney Gilstrap, who oversees more patent cases annually than virtually any other federal judge in the United States. This venue choice is rarely accidental among experienced PAE litigators.

The case was designated a Member Case within a consolidated structure, with Lead Case No. 2:25-cv-00377-JRG remaining active against presumably other defendants. This multi-defendant structure is a common Fabricant LLP tactical approach, allowing coordinated assertion while enabling surgical withdrawal from individual defendants.

Critically, Novo Nordisk had not yet answered the complaint nor moved for summary judgment at the time of dismissal — placing the timeline firmly in the pre-answer phase. No Markman hearing, claim construction order, or merits ruling was reached.

The Verdict & Legal Analysis

Outcome

On September 12, 2025, the court accepted and acknowledged Plaintiff’s Notice of Voluntary Dismissal Without Prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). All claims against Novo Nordisk were dismissed without prejudice. Each party was ordered to bear its own costs, expenses, and attorneys’ fees. No damages were awarded; no injunctive relief was granted or denied on the merits.

The Clerk was directed to close Member Case No. 2:25-cv-00376-JRG while maintaining Lead Case No. 2:25-cv-00377-JRG as active.

Procedural Analysis: What Rule 41(a)(1)(A)(i) Means Strategically

Rule 41(a)(1)(A)(i) permits a plaintiff to voluntarily dismiss a case as of right — without court approval — provided the defendant has not yet served an answer or motion for summary judgment. This is the procedural equivalent of a unilateral exit door, and its use here is strategically significant.

The without prejudice designation means Auto Injection Technologies retains the right to refile these same patent claims against Novo Nordisk in the future. This is not a concession on the merits. Rather, it reflects one or more of several likely strategic calculations:

• Settlement or licensing resolution reached off the record — the most common driver of pre-answer PAE dismissals
• Strategic prioritization — resources redirected toward the lead case or other defendants in the campaign
• Claim evaluation recalibration — plaintiff’s counsel may have assessed Novo Nordisk’s specific products and determined infringement exposure was weaker than initially mapped
• Defendant’s pre-answer pressure — while Novo Nordisk filed no formal motion, confidential correspondence or licensing negotiation may have influenced the withdrawal

Because no answer was filed, no invalidity counterclaims were formally raised, preserving both patents’ public validity records intact.

Legal Significance

The absence of a merits ruling means this case creates no direct precedent on the validity or infringement scope of US9387294B2 or US10201662B2. However, the dismissal without prejudice keeps the litigation threat active — a deliberate posture.

For the broader injection device patent landscape, this case signals continued assertion activity around auto-injector platform patents as pharmaceutical manufacturers scale GLP-1 and insulin delivery infrastructure globally.

Strategic Takeaways

• For Patent Holders & Assertion Entities: Pre-answer Rule 41 dismissals preserve optionality — withdraw, negotiate, and refile if necessary. Multi-defendant case structures allow targeted extraction from individual defendants without collapsing the broader campaign. E.D. Texas remains a preferred venue for pharmaceutical device patent assertions despite venue reform pressures.
• For Accused Infringers Like Novo Nordisk: Engaging experienced local counsel (The Dacus Firm) immediately upon service creates early negotiating leverage. Pre-answer settlement discussions, while not reflected in public filings, can effectively neutralize claims before costly discovery begins. Securing Freedom-to-Operate (FTO) analysis on US9387294B2 and US10201662B2 remains prudent given the without-prejudice dismissal.
• For R&D Teams: Auto-injector and drug delivery device development teams should ensure design documentation addresses claim elements of both patents. The without-prejudice dismissal means these patents remain enforceable — proactive FTO review is warranted.

Industry & Competitive Implications

The pharmaceutical injection device market — spanning auto-injectors, pen systems, and prefilled syringes — is experiencing unprecedented commercial pressure as GLP-1 therapies drive massive scale-up in injectable drug delivery demand. Novo Nordisk, with its Ozempic and Wegovy platforms, sits at the epicenter of this growth, making its injection device IP portfolio a natural target for patent assertion activity.

This case reflects a broader industry trend: PAEs are actively mapping injection device patent portfolios against the delivery hardware used by major pharmaceutical manufacturers. As biologics and GLP-1 therapies proliferate, the mechanical and engineering IP underlying their delivery systems becomes increasingly valuable — and increasingly litigated.

For companies in adjacent spaces — device manufacturers, contract development organizations, combination product developers — this case is a competitive intelligence signal. The patents asserted here may resurface in future litigation, and understanding their claim scope is commercially relevant.

Licensing negotiations in this space are typically confidential, but the rapid 156-day resolution strongly suggests a commercial resolution was reached, reflecting a market where pharmaceutical companies increasingly budget for injection device IP licensing as a cost of doing business.

❓ FAQ

What patents were involved in Auto Injection Technologies v. Novo Nordisk?

The case involved US9387294B2 (App. No. US13/498620) and US10201662B2 (App. No. US14/782667), both covering medicament injection device technology.

Why was the case dismissed?

Plaintiff Auto Injection Technologies LLC filed a voluntary dismissal without prejudice under Fed. R. Civ. P. 41(a)(1)(A)(i) before Novo Nordisk answered the complaint. No public reason was given; off-record settlement or strategic realignment are common explanations.

Can Auto Injection Technologies refile against Novo Nordisk?

Yes. A dismissal without prejudice preserves the plaintiff’s right to refile the same claims in future litigation, subject to applicable statutes of limitations.